Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off ...

Live Updates Live Coverage Has Ended Tempus AI sentiment heading 3:43 pm by Tempus enters earnings with strong tailwinds but ...

Q1 2025 Management View CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter of 2025, with year-over-year revenue ...

Elizabeth Krutoholow; VP, Investor Relations; Tempus AI Inc. Jim Rogers; Chief Financial Officer; Tempus AI Inc. Eric Lefkofsky; Chief Executive Officer, Director; T ...

Tempus AI Inc (TEM) reports a 75.4% revenue increase and a significant $200 million partnership, setting the stage for a promising fiscal year.

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication ...